MB710, an aminobenzothiazole derivative, stabilizes the oncogenic p53 mutation Y220C by binding tightly to the Y220C pocket, enhancing the stability of p53-Y220C with a dissociation constant (Kd) of 4.1 μM. This compound exhibits anticancer activity in cell lines harboring the p53-Y220C mutation [1].

MB710, tested across various cell lines for 72 hours, demonstrates low toxicity at doses up to 60 μM but begins to selectively decrease cell viability at higher concentrations. Specifically, in cancer cell lines NUGC3, NUGC4, WI38, and SW1088, MB710 exhibited IC50 values of 90, 120, >120, and >120 μM, respectively. Furthermore, MB710 displayed enhanced cytotoxicity at concentrations ranging from 0 to 120 μM in HUH-7 cells, particularly in the presence of the p53-Y220C mutation. A Cell Viability Assay across cell lines including NUGC3, HUH-7 with mutant p53 Y220C, NUGC4, and HUH-6 with wild-type p53, revealed MB710’s relatively low toxicity up to 60 μM, with NUGC3 being the most susceptible cell line.